ATLANTA, May 17, 2022--Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
ATLANTA, May 05, 2022--Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
The big shareholder groups in Alzamend Neuro, Inc. ( NASDAQ:ALZN ) have power over the company. Institutions often own...